8 Best Stocks to Buy According to Abrams Bison Investments

7. Acadia Healthcare Company, Inc. (NASDAQ:ACHC)

Abrams Bison Investments’ Equity Stake: $55.1 million

Number of Hedge Fund Holders: 42

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the Best Stocks to Buy According to Abrams Bison Investments. On May 19, Ryan Langston from TD Cowen maintained a “Buy” rating on the company’s stock, with a price objective of $44.00. This rating was backed by a combination of factors demonstrating Acadia Healthcare Company, Inc. (NASDAQ:ACHC)’s positive financial performance and strategic outlook. As per the analyst, the company posted a notable adjusted EBITDA beat, indicating a healthy start to 2025.

The analyst noted Acadia Healthcare Company, Inc. (NASDAQ:ACHC)’s proactive share repurchase program, reflecting a commitment to returning value to shareholders. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) highlighted that the year is setting up to be the largest bed expansion year in its history, building upon the record bed additions in 2024. During Q1 2025, the company made progress in catering to the strategic growth objectives, including the addition of 90 beds to existing facilities and 288 beds to new facilities, for a total of 378 newly licensed beds.

Additionally, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) added 7 new comprehensive treatment centers in Q1 2025, extending its market reach to 170 CTCs throughout 33 states. Moving forward, the company has a strong pipeline of potential opportunities in attractive markets and projects to add 608 beds annually over 2026 – 2028. Aristotle Capital Boston, LLC, an investment advisor, released its Q4 2024 investor letter. Here is what the fund said:

“Acadia Healthcare Company, Inc. (NASDAQ:ACHC), a behavioral healthcare and substance abuse treatment services company, continues to be impacted by the negative sentiment surrounding the news headlines related to patient care and questions about billing practices. While we take these developments seriously, we believe investors’ reaction to the news has been more severe than warranted. Industry peers have faced similar levels of scrutiny in the past with limited fundamental impact, and unless additional information is uncovered, we believe the current scrutiny will be resolved without much of an impact on their business. We continue to believe the company is well positioned to be an important part of the solution to an unfortunately growing need for behavioral health services.”